Azlocillin and Gentamicin

The combination of azlocillin and gentamicin represents a synergistic antibiotic pairing that leverages the complementary mechanisms of both drugs to enhance antimicrobial efficacy.

Mechanism of Action

Azlocillin is an acylampicillin (extended-spectrum penicillin) that works by binding to specific penicillin-binding proteins (PBPs) located inside bacterial cell walls. This binding inhibits the third and final stage of bacterial cell wall synthesis, leading to cell lysis mediated by bacterial autolytic enzymes. Azlocillin may also interfere with autolysin inhibitors, further promoting bacterial destruction.

Gentamicin, an aminoglycoside, binds to prokaryotic ribosomes, inhibiting protein synthesis in susceptible bacteria. This binding occurs at the 16S rRNA in helix 44 near the A site of the 30S ribosomal subunit, altering critical interactions and displacing important residues. This disruption has multiple negative effects on bacterial function, including inhibition of translation, initiation, elongation, and ribosome recycling.

Synergistic Effects

The combination of azlocillin and gentamicin demonstrates significant synergistic activity against multiple bacterial pathogens:

• Pseudomonas aeruginosa: The combined effect is synergistic against many strains of this difficult-to-treat pathogen
• Staphylococcus aureus: Synergistic effects are frequently observed
• Enterobacteriaceae: Enhanced killing is seen against many members of this family
• Enterococcal strains: While gentamicin combined with penicillins shows synergy against Enterococcus species, specific data on azlocillin-gentamicin for enterococci is limited

The synergistic effect is typically more pronounced against organisms with low sensitivity to azlocillin and less pronounced against organisms resistant to aminoglycosides.

Pharmacokinetic Considerations

When used together, azlocillin may decrease the serum concentration of gentamicin, potentially affecting dosing requirements. This interaction should be considered when administering the combination.

Clinical Applications

This antibiotic combination is particularly valuable for treating:

• Serious infections caused by Pseudomonas aeruginosa
• Mixed infections involving both gram-positive and gram-negative pathogens
• Life-threatening infections where broad-spectrum coverage is needed before culture results are available

Administration

Both medications are administered parenterally, with gentamicin typically given intravenously in hospitalized patients. Dosing should be carefully monitored, particularly for gentamicin, which requires therapeutic drug monitoring to prevent toxicity.

Limitations

It's important to note that there is no general rule to predict with certainty whether this antibiotic combination will act synergistically on a specific bacterial strain. Additionally, bacteria resistant to one aminoglycoside may be resistant to others, potentially limiting effectiveness in some cases.